OBJECTIVE: The objective of this study is to assess lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with pancreatic ductal adenocarcinoma. METHODS: Magnetic resonance imaging was performed in 13 patients with known or high index of suspicion of pancreatic cancer and who were scheduled for surgical resection. Protocols included T2*-weighted imaging before and after administration of Ferumoxytol (Feraheme) for the evaluation of lymph node involvement. Eleven of the 13 patients underwent a Whipple procedure and lymph node dissection. Nodes that lacked contrast uptake were deemed malignant, and those that demonstrated homogeneous uptake were deemed benign. RESULTS: A total of 264 lymph nodes were resection, of which 17 were malignant. The sensitivity and specificity of LNMRI was 76.5% and 98.4% at a nodal level and 83.3% and 80% at a patient level. CONCLUSION: LNMRI demonstrated high sensitivity and specificity in patients with pancreatic ductal adenocarcinoma.
OBJECTIVE: The objective of this study is to assess lymphotropic nanoparticle-enhanced magnetic resonance imaging (LNMRI) in identifying malignant nodal involvement in patients with pancreatic ductal adenocarcinoma. METHODS: Magnetic resonance imaging was performed in 13 patients with known or high index of suspicion of pancreatic cancer and who were scheduled for surgical resection. Protocols included T2*-weighted imaging before and after administration of Ferumoxytol (Feraheme) for the evaluation of lymph node involvement. Eleven of the 13 patients underwent a Whipple procedure and lymph node dissection. Nodes that lacked contrast uptake were deemed malignant, and those that demonstrated homogeneous uptake were deemed benign. RESULTS: A total of 264 lymph nodes were resection, of which 17 were malignant. The sensitivity and specificity of LNMRI was 76.5% and 98.4% at a nodal level and 83.3% and 80% at a patient level. CONCLUSION: LNMRI demonstrated high sensitivity and specificity in patients with pancreatic ductal adenocarcinoma.
Authors: Mansi Saksena; Mukesh Harisinghani; Peter Hahn; John Kim; Anuradha Saokar; Benjamin King; Ralph Weissleder Journal: AJR Am J Roentgenol Date: 2006-12 Impact factor: 3.959
Authors: Steven F Petit; Binbin Wu; Michael Kazhdan; André Dekker; Patricio Simari; Rachit Kumar; Russel Taylor; Joseph M Herman; Todd McNutt Journal: Radiother Oncol Date: 2011-06-15 Impact factor: 6.280
Authors: Christine A Iacobuzio-Donahue; Victor E Velculescu; Christopher L Wolfgang; Ralph H Hruban Journal: Clin Cancer Res Date: 2012-08-15 Impact factor: 12.531
Authors: Saila P Kauhanen; Gaber Komar; Marko P Seppänen; Kirsti I Dean; Heikki R Minn; Sami A Kajander; Irina Rinta-Kiikka; Kalle Alanen; Ronald J Borra; Pauli A Puolakkainen; Pirjo Nuutila; Jari T Ovaska Journal: Ann Surg Date: 2009-12 Impact factor: 12.969
Authors: David Hasan; Nohra Chalouhi; Pascal Jabbour; Aaron S Dumont; David K Kung; Vincent A Magnotta; William L Young; Tomoki Hashimoto; H Richard Winn; Donald Heistad Journal: Stroke Date: 2012-11-08 Impact factor: 7.914
Authors: Krista J Hachey; Denis M Gilmore; Katherine W Armstrong; Sean E Harris; Jason L Hornick; Yolonda L Colson; Jon O Wee Journal: J Thorac Cardiovasc Surg Date: 2016-04-11 Impact factor: 5.209